Assignee
GANYMED PHARMACEUTICALS GMBH
DE·6 granted patents·6 pending applications·13 citations·filing 2016–2023
Top patents by PatentIndex Score
12 records- 0193US11859008B2Antibodies for treatment of cancer expressing claudin 6GANYMED PHARMACEUTICALS GMBH·Filed 2020·Granted Jan 2, 2024·2 cites·12 claims
- 0289US10017564B2Monoclonal antibodies against claudin-18 for treatment of cancerGANYMED PHARMACEUTICALS GMBH·Filed 2016·Granted Jul 10, 2018·6 cites·21 claims
- 0387US10927413B2Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosisGANYMED PHARMACEUTICALS GMBH·Filed 2016·Granted Feb 23, 2021·3 cites·21 claims
- 0485US2024092896A1Antibodies specific for claudin 6 (cldn6)GANYMED PHARMACEUTICALS GMBH·Filed 2023·Application pending·0 cites
- 0584US2024101703A1Antibodies for treatment of cancer expressing claudin 6GANYMED PHARMACEUTICALS GMBH·Filed 2023·Application pending·0 cites
- 0683US2024084033A1Cancer therapy using cldn6 target-directed antibodies in vivoGANYMED PHARMACEUTICALS GMBH·Filed 2023·Application pending·0 cites
- 0780US11541127B2Drug conjugates comprising antibodies against claudin 18.2GANYMED PHARMACEUTICALS GMBH·Filed 2016·Granted Jan 3, 2023·2 cites·28 claims
- 0877US2023193261A1Methods and compositions for diagnosis and treatment of cancerGANYMED PHARMACEUTICALS GMBH·Filed 2022·Application pending·0 cites
- 0971US11858988B2Antibodies specific for claudin 6 (CLDN6)GANYMED PHARMACEUTICALS GMBH·Filed 2020·Granted Jan 2, 2024·0 cites·24 claims
- 1071US11395852B2Therapy involving antibodies against Claudin 18.2 for treatment of cancerGANYMED PHARMACEUTICALS GMBH·Filed 2018·Granted Jul 26, 2022·0 cites·19 claims
- 1170US2023270878A1Drug conjugates comprising antibodies against claudin 18.2GANYMED PHARMACEUTICALS GMBH·Filed 2022·Application pending·0 cites
- 1269US2021079113A1Cancer therapy using cldn6 target-directed antibodies in vivoGANYMED PHARMACEUTICALS GMBH·Filed 2020·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →